Nabriva Therapeutics plc: Nasdaq/NYSE listing notice — Nabriva receives Nasdaq delisting notice over negative equity of -$4.4M

Nabriva Therapeutics plc

Stockholders' equity of -$4,357,000 as of March 31, 2023, below $2.5M minimum.
Nasdaq letter received May 25, 2023; company has until July 10, 2023 to submit compliance plan.
If plan accepted, extension of up to 180 days from May 25 may be granted.
Alternative listing standards (market value or net income) not currently met.
No immediate impact on listing but delisting risk if compliance not regained.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Nabriva Therapeutics plc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 25, 2023, Nabriva Therapeutics plc (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity (deficit) of the Company of $(4,357,000) as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, was below the minimum stockholders’ equity requirement of $2,500,000. As of the date of this Current Report on Form 8-K, the Company does not meet the alternative standards for continui

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-067071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.